Label: information for the user
Pranzo 62.5/1.25/0.5 mg/ml
oral solution
Hydrochloride carnitine
Lysine hydrochloride
Ciproheptadine hydrochloride
Read this label carefully before starting to take this medicine, because it contains important information for you.
Follow exactly the administration instructions of the medicine contained in this label or those indicated by your doctor or pharmacist.
You should consult a doctor if you worsen or do not improve after 30 days.
6. Contents of the pack and additional information
Pranzo is an appetite stimulant medication and is indicated for the symptomatic treatment of anorexia.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Pranzo.
-If you have a history of bronchial asthma, hyperthyroidism, cardiovascular diseases, hypertension, and increased intraocular pressure.
The good taste of Pranzo may induce children to ingest excessive amounts of the medication, so it is advisable to keep it out of their reach.
Do not administer to children under 2 years old.
Other medications and Pranzo
Inform your doctor or pharmacist if you are taking or have taken recently or may have to take another medication.
It is not advisable to take it together with barbiturates, benzodiazepines, and other central nervous system depressants, selective serotonin reuptake inhibitors such as fluoxetine, alkalinizers, sympathomimetics, oral anticoagulants, estrogens, progesterone, phenytoin, griseofulvin, and MAO inhibitors.
Pranzo intake with food, drinks, and alcohol
It is not advisable to take this medication together with alcoholic beverages.
Pranzo should be taken before meals.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Avoid administering this medication during pregnancy and breastfeeding.
Driving and operating machinery:
It is not recommended to drive vehicles, or operate hazardous or precision machinery (it may reduce driving ability and reflexes).
Pranzo contains saccharose, ethanol, propylparaben, sodium chloride (E-217), amaranth (E-123), and sodium.
This medication contains saccharose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
Patients with diabetes mellitus should note that this medication contains 0.6 g of saccharose per dose of 2 ml, or 1.2 g of saccharose per dose of 4 ml.
It may cause tooth decay.
This medication contains 97.8 mg of ethanol (alcohol) per dose of 2 ml or 195.7 mg of ethanol (alcohol) per dose of 4 ml, which is equivalent to a 4.89% concentration.The amount of 2 ml of this medication is equivalent to less than 2.5 ml of beer or 1 ml of wine. The amount of 4 ml of this medication is equivalent to 5 ml of beer or 2 ml of wine.
It is unlikely that the amount of alcohol contained in this medication will have any noticeable effect on adults or adolescents. It may have some effects on young children, such as drowsiness.
The amount of alcohol contained in this medication may alter the effect of other medications. Consult your doctor or pharmacist if you are taking other medications.
If you are pregnant or breastfeeding, consult your doctor or pharmacist before taking this medication.
If you have an alcohol addiction, consult your doctor or pharmacist before taking this medication.
It may cause allergic reactions (possibly delayed) because it contains propylparaben, sodium chloride (E-217).
This medication may cause allergic reactions because it contains amaranth (E-123).It may provoke asthma, especially in patients allergic to acetylsalicylic acid.
This medication contains less than 23 mg of sodium (1 mmol) per ml; it is essentially "sodium-free."
This medication is taken using the double 2 ml and 4 ml measuring spoon.
Take this medication before meals.
Use in adults:
The recommended daily dose is 1 large spoonful (4 ml) per every 10 kg of weight.
The total must be divided into 3 or 4 doses per day. Do not exceed more than 5 spoonfuls of 4 ml per day (20 ml).
Use in children:
The recommended daily dose is 1 small spoonful (2 ml) per every 4 kg of weight.
As a guideline, the following dosing schedule is recommended:
Body weight approximate in kg | Dosage ml per day | Spoonfuls of 2 ml | Divided into 3 or 4 doses per day |
8 to12 kg | 4 to6 ml | 2 to3 | |
13 to16 kg | 6 to8 ml | 3 to4 | |
17 to20 kg | 8 to10 ml | 4 to5 | |
21 to24 kg | 10 to12 ml | 5 to6 | |
25 to28 kg | 12 to14 ml | 6 to7 | |
29 to32 kg | 14 to16 ml | 7 to8 | |
33 to36 kg | 16 to18 ml | 8 to9 | |
37 to40 kg | 18 to20 ml | 9 to10 |
If symptoms worsen or persist after 30 days, you must consult a doctor.
Intoxication, produced only by very high doses above the therapeutic dose, causes drowsiness and sometimes, contrarily, convulsions. It must be treated by qualified personnel with stomach washes, sedatives if necessary, and respiratory stimulants.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Pranzo
Do not take a double dose to compensate for the missed doses. Take it when you remember and the next doses with the indicated separation (3-4 doses per day).
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
The adverse effects listed below are classified according to their frequency and by organ and system. The frequency categories are defined by the following convention: very common (affects more than 1 in 10 people); common (affects up to 1 in 100 people); uncommon (affects up to 1 in 1000 people); rare (affects between 1 and 10 in 10,000 people); very rare (affects fewer than 1 in 10,000 people); frequency not known (cannot be estimated from available data).
Common: may affect up to 1 in 10 people:
Drowsiness and somnolence. In children, these effects may be desirable as they reduce emotional tension, often associated with anorexia.
Uncommon: may affect up to 1 in 100 people:
Mouth dryness, dizziness, nervousness, weakness, dry mucous membranes, headache, nausea, and dermatological allergic manifestations such as rash and edema.
Rare: may affect up to 1 in 1000 people:
Central nervous system stimulation (such as agitation, confusion, visual hallucinations).
In patients with renal insufficiency, carnitine administration may cause myasthenia.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use website:www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not use this medication if you observe visible signs of deterioration or if the bottle is open.
Medications should not be disposed of through drains or in the trash.Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, please ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Appearance of the product and contents of the packaging
Pranzo is an oral solution of pink color.
It is presented in white opaque plastic bottles with a screw cap and seal, along with a double dosing spoon (2 ml and 4 ml).
The contents of the packaging are 200 ml of oral solution.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Laboratorios Viñas, S.A.
Provenza, 386
08025 - Barcelona
Spain
Responsible for manufacturing
Laboratorios Viñas, S.A.
Torrent d’en Vidalet, 29
08012 - Barcelona
Spain
Last review date of this prospectus: May 2010
The detailed information of this medicine is available on the webpage of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.